Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan-Reference-Cited by-同舟云学术

Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan

Published:2019-03-01 Issue:3 Volume:5 Page:343
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Cremolini Chiara¹,Rossini Daniele¹,Dell’Aquila Emanuela²,Lonardi Sara³,Conca Elena⁴,Del Re Marzia⁵,Busico Adele⁴,Pietrantonio Filippo⁶,Danesi Romano⁵,Aprile Giuseppe⁷⁸,Tamburini Emiliano⁹,Barone Carlo¹⁰,Masi Gianluca¹,Pantano Francesco²,Pucci Francesca¹¹,Corsi Domenico C.¹²,Pella Nicoletta⁷,Bergamo Francesca³,Rofi Eleonora⁵,Barbara Cecilia¹³,Falcone Alfredo¹,Santini Daniele²

Affiliation:

1. Unit of Medical Oncology 2, Department of Translational Research and New Technologies in Medicine and Surgery, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy

2. Department of Medical Oncology, Campus Bio-Medico University of Rome, Rome, Italy

3. Medical Oncology Unit 1, Clinical and Experimental Oncology Department, Veneto Institute of Oncology Istituto Oncologico Veneto–Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy

4. Department of Diagnostic Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

5. Clinical Pharmacology and Pharmacogenetics Unit, Department of Clinical and Experimental Medicine, Pisa, Italy

6. Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

7. Department of Oncology, University and General Hospital, Udine, Italy

8. Department of Oncology, General Hospital San Bortolo, Unità Locale Socio-Sanitaria 8 Berica, Vicenza, Italy

9. Department of Medical Oncology, Infermi Hospital, Rimini, Italy

10. Medical Oncology Unit, Università Cattolica del Sacro Cuore, Rome, Italy

11. Medical Oncology Unit, University Hospital, Parma, Italy

12. Medical Oncology Unit, Fatebenefratelli–Isola Tiberina Hospital, Rome, Italy

13. Medical Oncology Unit, Presidio Ospedaliero Felice Lotti, Pontedera, Italy

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

http:///jamaoncology/article-pdf/5/3/343/17345728/jamaoncology_cremolini_2018_oi_180093.pdf

Reference37 articles.

1. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.;Van Cutsem;Ann Oncol,2016

2. Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM).;Salvatore;ESMO Open,2017

3. Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?;Santini;Ann Oncol,2012

4. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.;Siravegna;Nat Med,2015

5. Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer.;Van Emburgh;Nat Commun,2016

Cited by 323 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Third-line treatment and beyond in metastatic colorectal cancer: What do we have and what can we expect?;Critical Reviews in Oncology/Hematology;2024-10

2. Successful cetuximab rechallenge in metastatic colorectal cancer: A case report;World Journal of Clinical Oncology;2024-09-24

3. Gefitinib Resensitization After a TKI-Free Interval in Osimertinib Resistant Non-Small-Cell Lung Cancer: A Glimpse of Hope in Time of Crisis?;CLIN LUNG CANCER;2024

4. New Perspectives in Colorectal Cancers Treatment, the Role of MicroRNAs;Current Drug Targets;2024-09

5. Rationale and design of the COPERNIC Trial: a study of on-treatment ctDNA changes in chemo-refractory colorectal cancer patients;Clinical Colorectal Cancer;2024-09